Secukinumab demonstrates high sustained efficacy and a favorable safety profile through five years of treatment in moderate-to-severe psoriasis

Background: Secukinumab, a fully human monoclonal antibody that neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis, demonstrating sustained high levels of efficacy with a favorable safety profile. Here we report secukinumab's long-term sustainability and safety through 5 years of continuous treatment at the approved dose.